Objective: To review recent clinical pharmacokinetic and pharmacodynamic data to optimize dosing regimens for polymyxin B and colistin for treatment of infections due to A. baumannii.
Methods: A literature search was performed using the search terms Acinetobacter, polymyxin, colistin, polymyxin B on MEDLINE. Additional references were identified from the resulting citations.
Results: Increasing the dose of polymyxin B or colistin and using either in combination with other antibiotic agents demonstrates improved antimicrobial activity against Acinetobacter spp. Polymyxin B, unlike colistin, is available as an active drug and appears to be relatively unaffected by renal function. This is advantageous both for patients with renal impairment and for those with intact renal function. Achieving therapeutic serum concentrations of colistin may be difficult for those with intact renal function due to rapid clearance of the prodrug, colistimethate sodium (CMS). Clinical data are still lacking for polymyxin B, and it remains to be seen whether advantages demonstrated in PK/PD analyses will persist in the larger scale of patient care and safety.
Conclusions: The use of higher doses of either colistin or polymyxin B, as well as combination with other antibiotics, may prevent emerging resistance and preserve the activity of polymyxins against A. baumannii.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.ijid.2014.10.014 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Structural and functional analysis of the lipoprotein chaperone LolA.
Front Microbiol
December 2024
Umeå Centre for Microbial Research (UCMR), Umeå University, Umeå, Sweden.
Lipoproteins are crucial for maintaining the structural integrity of bacterial membranes. In Gram-negative bacteria, the localization of lipoprotein (Lol) system facilitates the transport of these proteins from the inner membrane to the outer membrane. In , an ε-proteobacterium, lipoprotein transport differs significantly from the canonical and well-studied system in , particularly due to the absence of LolB and the use of a LolF homodimer instead of the LolCE heterodimer.
View Article and Find Full Text PDFAntimicrobial activity and synergistic effect of phage-encoded antimicrobial peptides with colistin and outer membrane permeabilizing agents against .
PeerJ
December 2024
Department of Microbiology and Parasitology, Faculty of Medical Science, Naresuan University, Muang, Phitsanulok, Thailand.
Background: poses a significant public health threat. Phage-encoded antimicrobial peptides (AMPs) have emerged as promising candidates in the battle against antibiotic-resistant .
Methods: Antimicrobial peptides from the endolysin of bacteriophage were designed from bacteriophage vB_AbaM_PhT2 and vB_AbaAut_ChT04.
Unravelling the mechanisms causing murepavadin resistance in : lipopolysaccharide alterations and its consequences.
Front Cell Infect Microbiol
December 2024
Servicio de Microbiología, Hospital Universitario Ramón y Cajal, Instituto Ramón y Cajal de Investigación Sanitaria (IRYCIS), Madrid, Spain.
Introduction: Murepavadin is an antimicrobial peptide (AMP) in clinical development that selectively targets LptD and whose resistance profile remains unknown. We aimed to explore genomic modifications and consequences underlying murepavadin and/or colistin susceptibility.
Methods: To define genomic mechanisms underlying resistance, we performed two approaches: 1) a genome-wide association study (GWAS) in a clinical collection (n=496), considering >0.
A systematic review and meta-analysis: rising prevalence of colistin resistance in ICU-acquired Gram-negative bacteria.
APMIS
January 2025
Laboratory Sciences Research Center, Golestan University of Medical Sciences, Gorgan, Iran.
Colistin is a last-resort treatment for multidrug-resistant Gram-negative bacterial infections, particularly in critically ill patients. Nevertheless, it remains a major threat to public health. We assessed the proportion of colistin-resistant Gram-negative isolates from intensive care unit (ICU) infections in different years, areas, pathogens, and antimicrobial susceptibility tests (AST).
View Article and Find Full Text PDFInvestigation of colistin heteroresistance and the colistin resistance genes mcr-1 to mcr-5 in Escherichia coli and Klebsiella pneumoniae isolates in a tertiary hospital in Turkey.
J Infect Dev Ctries
November 2024
Department of Medical Microbiology, Faculty of Medicine, Trakya University, Edirne, Turkey.
Introduction: Heteroresistance is not detected by traditional antimicrobial susceptibility testing methods and may lead to treatment failures. Investigating the presence of plasmid-mediated colistin resistance genes is important because of the horizontal transmission of the relevant genes between bacterial species. This study aimed to investigate the presence of colistin heteroresistance and the colistin resistance genes mcr-1 to mcr-5 in Escherichia coli and Klebsiella pneumoniae isolates.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!